As a key note speaker at international scientific conference ESPCR European Society for Paediatric Clinical Research, 23rd Meeting, 20 June 2014, I have reviewed the state-of-the art in genetics and pharmacogenomics of chronic inflammatory diseases focusing on Inflammatory bowel disease and translations of scientific discoveries into clinical practice.
B.04 Guest lecture
COBISS.SI-ID: 512411192As a key note speaker at scientific international conference 45th Professor Janez Plecnik Memorial Meeting with international symposium Inflammatory bowel disease,Ljubljana 4. 12.-5.12. 2014, I have reviewed the state-of-art in genetics and pharmacogenomics ofInflammatory bowel disease and translations of scientific discoveries into clinical practice.
B.04 Guest lecture
COBISS.SI-ID: 512463928We presented our initial results of our pharmacogenomics study of Crohn diseases patients enrolled in treatment with biological drug adalimumab (inhibitor TNF alpha); at international scientific conference "The European Human Genetics Conference 2014 Milan, Italy, May 31 - June 3, 2014, organized by "European Society of Human Genetics (ESHG). To the best of our knowledge our prospective pharmacogenomics study is the first of this kind. First results of our study suggest response to adalimumab in Crohn disease is genetically predisposed and that candidate genes include genes contributing to disease pathogenesis such as ATG16L1.
B.03 Paper at an international scientific conference
COBISS.SI-ID: 512407608